Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma

AIM:To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin- like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy. METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy. RESULTS: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03). CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.

The efficacy of fluoropyrimidine.based adjuvant chemotherapy on biliary tract cancer after R0 resection

Background: The optimal treatment strategy for biliary tract cancer(BTC) after curative?intent resection remains con?troversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine?based adjuvant chemotherapy for BTC patients undergoing microscopically margin?negative(R0) resection.Methods: We retrospectively analyzed the clinical data of BTC patients who underwent curative?intent R0 resection. Patients were eligible if they received either fluoropyrimidine?based adjuvant chemotherapy or observation after R0 resection.Results: A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5?year overall survival(OS) rates(48.4% vs. 39.6%, P = 0.439) or 3?year recurrence?free survival(RFS) rates(49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine?based adjuvant chemotherapy or observation. However, for patients with stages Ⅱ and Ⅲ BTC, chemotherapy significantly improved 5?year OS rate(52.4% vs. 35.6%, P = 0.002) and 3?year RFS rate(55.5% vs. 39.1%, P = 0.021) compared with observation.Conclusion: Fluoropyrimidine?based adjuvant chemotherapy may prolong the survival of patients with stages Ⅱ and Ⅲ BTC after R0 resection.

氟嘧啶为基础的辅助化疗对胆道癌R0切除术后疗效的观察

背景与目的胆道癌(biliary tract cancer,BTC)根治性切除术后的最佳治疗方案仍存有争议。本研究旨在评价以氟嘧啶为基础的辅助化疗对显微镜下切缘阴性(R0)切除BTC患者的疗效。方法回顾分析行根治性R0切除的BTC患者的临床资料。将R0切除术后接受以氟嘧啶为基础的辅助化疗或单纯R0切除的患者纳入本研究。结果本研究共纳入153例患者。对于全体患者,接受以氟嘧啶为基础的辅助化疗组患者与对照组患者的5年总生存(overall survival,OS)率(48.4%vs. 39.6%,P=0.439)和3年无复发生存(recurrence-free survival,RFS)率(49.1%vs. 39.5%,P=0.299)无显著差异。而对于Ⅱ、Ⅲ期BTC患者,化疗组比对照组的5年OS率(52.4%vs.35.6%,P=0.002)和3年RFS率(55.5%vs. 39.1%,P=0.021)有显著提高。结论以氟嘧啶为基础的辅助化疗可延长Ⅱ、Ⅲ期BTC患者R0切除术后的生存。